The impact of stereoisomerism in bioequivalence studies.
Midha
K K
KK
Drug Metabolism Drug Disposition Group, College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan, Canada, S7N 5C9.
McKay
G
G
Rawson
M J
MJ
Hubbard
J W
JW
D018759:Adrenergic Uptake Inhibitors / Q000493:pharmacokinetics; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics; D004316:Doxepin / Q000493:pharmacokinetics; D005480:Flurbiprofen / Q000493:pharmacokinetics; D006801:Humans; D006886:Hydroxychloroquine / Q000493:pharmacokinetics; D007660:Ketoprofen / Q000493:pharmacokinetics; D009248:Nadolol / Q000493:pharmacokinetics; D009661:Nortriptyline / Q000493:pharmacokinetics; D011405:Propafenone / Q000493:pharmacokinetics; D013237:Stereoisomerism; D013810:Therapeutic Equivalency
D018759:Adrenergic Uptake Inhibitors; D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004316:Doxepin; D009248:Nadolol; D006886:Hydroxychloroquine; D005480:Flurbiprofen; D011405:Propafenone; D007660:Ketoprofen; D009661:Nortriptyline